Drug intelligence / Profile preview

TAN-118

Development stage: Unknown
Lead developer: Shanghai Thederma
Modality: Small Molecules
Administration: Oral

Overview

TAN-118 is a small molecule chemical drug developed by Shanghai Thederma Pharmaceuticals. It is being investigated primarily for the treatment of immune system diseases and digestive system disorders, with a focus on inflammatory bowel diseases. As of April 2025, its highest global development status is Phase 1 clinical trials. The available data indicate that it is administered orally and has been evaluated in healthy adult subjects for safety, tolerability, pharmacokinetics, and food effect. Specific molecular targets or mechanisms of action have not been publicly disclosed.

Beyond the preview

Go deeper on TAN-118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAN-118.

Explore the full profile